OncoQR ML GmbH Company Profile, Contacts & Intelligence

Biotechnology ResearchVienna, At3 employeesFounded 2013
3 contacts with email or phone data3 with email data
View verified contacts Compare competitors
Employees
3
Company source estimate
Reachable Contacts
3
Visible contacts with email or phone data
Contacts With Email
3
3 of 3 visible contacts
Departments
2
Mapped contact coverage

OncoQR ML GmbH Overview

Privately held OncoQR ML, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodeler) technology platform. Unlike any other currently available therapy, the platform is capable of boosting the patient’s immune system to generate a strong, specific and controlled immune response against cancer. This “Active Checkpoint Control Immunotherapy” activates all four naturally available tumour killing mechanisms of the immune system without triggering side effects. The company’s lead candidate OQR100 (TYG100), co-developed with TYG Oncology Ltd. and CR-UK, targets pancreatic cancer and induces neutralizing antibodies against gastrin, a major growth factor for pancreatic- and other forms of gastric cancer. OQR200 is directed against HER2/neu over-expressing breast cancer and induces strong polyclonal humoral (IgG and IgA) and cellular (CD4 and CD8) immune responses, superior to trastuzumab, pertuzumab or passive checkpoint inhibitors. Both lead candidates, which have achieved in vivo Proof of Concept in non-human primates, as well as the S-TIR™ technology platform are now available for out-licensing. For further information visit www.oncoqr.com. + Cancer immunotherapy + Active therapy (protein/peptide based) + Checkpoint Control + No side effects + Activation of all 4 naturally available killing mechanisms of the immune system + Multiple cancer targets

Headquarters
Vienna, At
Website
oncoqr.com
Industry
Biotechnology Research
Founded
2013
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Active Checkpoint Control Immunotherapy Cancer Immunotherapy Cancer Vaccine Immunooncology Life Science S-TIR (TM) Technology

OncoQR ML GmbH Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

3 contacts with contact data
3 with email data in the visible sample.
2 departments represented
Visible contacts with email or phone data are mapped to these departments.
2 company-domain emails
Visible contacts using OncoQR ML GmbH's company email domain.
Executive
1
General
1

OncoQR ML GmbH People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

L
Liesbeth Mudde-Boer
Scientist at Oncoqr ML Gmbh
E
G
Geert C. Mudde
Cso and Founder at Oncoqr ML, S-target
E
C
Christof Langer
Managing Director & Founder
E

OncoQR ML GmbH Workforce Composition

Seniority breakdown across 3 visible profiles.

Executive
2
Individual contributor
1

OncoQR ML GmbH Technology & Talent

Technology-related job titles represented in the visible people data.

Data / AI
2

Compare Similar Companies to OncoQR ML GmbH

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
The Mannheimer Foundation, Inc. Veterinary Services 31 View company
Attoquant Diagnostics GmbH Biotechnology Research 8 View company
APEIRON Biologics AG Biotechnology Research 5 View company
Themis Bioscience GmbH Multi-signal peer 5 View company
Aposcience AG Biotechnology Research 4 View company
IMPROCESS GmbH Biotechnology Research 3 View company
GH BioQuenta Consulting e.U. Business Consulting And Services 2 View company
S-TARget therapeutics Biotechnology Research 1 View company
Mycoplasma Biosafety Biotechnology Research Not listed View company
Panoptes Pharma GES.M.B.H Research Services Not listed View company